Best Paper
Anno 2023
- Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
- HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
- Genomics to select treatment for patients with metastatic breast cancer
Anno 2022
- Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Anno 2021
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- Fasting-mimicking diet and hormone therapy induce breast cancer regression (2020)
Anno 2020
- Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
- Trastuzumab Emtansine for Residual Invasive HER2- Positive Breast Cancer (NEJM 2019)
- PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Anno 2019
- Adjuvant anastrozole versus exemestane versus letrozole
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Anno 2017
- 2017 – In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
- 2017 – Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
- 2017 – Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Anno 2015
- 2015 – Measures of Outcome inMetastatic Breast Cancer: Insights From a Real-World Scenario
- 2015 – Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole- Lapatinib in Postmenopausal Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Operable Breast Cancer
- 2015 – Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Anno 2014
Anno 2013
Anno 2012
Anno 2011
Anno 2009
Con il Patrocinio di:
Progetto realizzato da:
